---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-019868"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T16:56:37.283208+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025

## Summary
- Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
- Shares outstanding post-offering: 8,976,914.
- EXXUA is first-in-class oral 5HT1a receptor agonist for MDD; no sexual dysfunction warning; studied in >5,000 patients.
- Conference call June 11, 2025 at 4:30 p.m. ET to detail EXXUA commercialization plan.
- Net proceeds for working capital and to fund EXXUA launch; expects FDA-approved product to enter $22B U.S. MDD market.

## SEC filing metadata
- accession: 0001437749-25-019868
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925019868/0001437749-25-019868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925019868/aytu20250609_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-019868
- JSON: https://secwatch.observer/filing/0001437749-25-019868.json
- Plain text: https://secwatch.observer/filing/0001437749-25-019868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.